Real-World Treatment Outcomes and Prognostic Factors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer: A Single-Center Study from a High-Volume Tertiary Chest Hospital

Background/Objectives: Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is a distinct molecular subgroup responsive to EGFR tyrosine kinase inhibitors (TKIs). This study evaluated real-world treatment outcomes and prognostic factors in patients with EGFR-mutated metastatic NSCLC.

Methods

This retrospective study included 124 patients treated with first-line EGFR-TKIs between January 2017 and 30 August 2025 at a tertiary center. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were assessed using Cox proportional hazards models.